Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 2,000 shares at $24.44 on Jan. 8, 2014. Following this transaction, the SVP Software Development owned 841,517 shares meaning that the stake was reduced by 0.24% with the 2,000-share transaction.

The shares most recently traded at $23.38, down $1.06, or 4.53% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 51,000
  • 24-Week # shares sold: 110,000

The average volume for Interactive Brokers Group has been 540,800 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.2 billion and is part of the financial sector and financial services industry. Shares are down 4.48% year-to-date as of the close of trading on Wednesday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.65%. The company has a P/E ratio of 28.1. Currently there are 2 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants